Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Lorenz Thurner, MD, Viola Poeschel, MD, Bettina Altmann, PhD, Herve Tilly, MD PhD, Marc Andre, MD, Marie Maerevoet, MD, Thomas Weber, MD, Joerg Hoffmann, MD, Martin Dreyling, MD, Herve Maisonneuve, MD, Andrea Kerkhoff, MD, Steven Le Gouill, MD PhD, Stephan Stilgenbauer, MD, Marita Ziepert, PhD, Roch Houot, MDPhD, Corinne Haioun, MDPhD, Gerhard Held, MD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-139459

Published: 2020

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Moritz Bewarder, MD, Gerhard Held, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, MD, Arne Felbel, Dominic Kaddu-Mulindwa, MD, Niels Murawski, MD, Stephan Stilgenbauer, Frank Neumann, PhD

Blood (2019) 134 (Supplement_1): 5616.

https://doi.org/10.1182/blood-2019-126998

Published: 2019

Journal Articles

Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma

Lorenz Thurner, MD, Sylvia Hartmann, MD, Theresa Bock, Natalie Fadle, Maria Kemele, Evi Regitz, Moritz Bewarder, MD, Sigrun Smola, Thorsten Pfuhl, Jana Held, Rainer-Maria Bohle, Laurence de Leval, MD, Rabea Wagener, Reiner Siebert, PhD, Martin-Leo Hansmann, Stephan Stilgenbauer, MD PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD

Blood (2018) 132 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2018-99-114209

Published: 2018

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

Moritz Bewarder, MD, Lorenz Thurner, MD, Frank Neumann, PhD, Natalie Fadle, Evi Regitz, Maria Kemele, Helene Will, Lisa Goerens, Konstantinos Christofyllakis, MD, Dominic Kaddu-Mulindwa, MD, Stephan Stilgenbauer, Maximilian Kiefer, Klaus Dieter Preuss, PhD

Blood (2018) 132 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2018-99-115348

Published: 2018

Journal Articles

B-Cell Receptor Antigens As the Targeting Moiety for Bispecific Constructs - a Novel Treatment Approach for B-Cell Lymphomas

Moritz Bewarder, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Evi Regitz, Natalie Fadle, Michael Pfreundschuh, MD

Blood (2017) 130 (Supplement 1): 111.

https://doi.org/10.1182/blood.V130.Suppl_1.111.111

Published: 2017

Journal Articles

CD3/Bars: A Novel Bispecific Format for the Treatment of B-Cell Lymphomas

Moritz Bewarder, MD, Klaus-Dieter Preuss, PhD, Natalie Fadle, Evi Regitz, Lorenz Thurner, MD, Michael Pfreundschuh, MD, PhD

Blood (2016) 128 (22): 3516.

https://doi.org/10.1182/blood.V128.22.3516.3516

Published: 2016

Journal Articles

LRPAP1 Is a Frequent B-Cell Receptor Antigen in Mantle Cell Lymphoma (MCL)

Lorenz Thurner, MD, Sylvia Hartmann, Klaus-Dieter Preuss, PhD, Natalie Fadle, Maria Kemele, Evi Regitz, Christiane Pott, MD PhD, Rainer-Maria Bohle, Martin-Leo Hansmann, Michael Pfreundschuh, MD

Blood (2015) 126 (23): 2685.

https://doi.org/10.1182/blood.V126.23.2685.2685

Published: 2015

Journal Articles

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD, Lorenz Thurner, MD, Stefan Barth, Prof.Dr., Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, PhD, Thomas Nachreiner, Dr., Klaus-Dieter Preuss, PhD

Blood (2015) 126 (23): 3995.

https://doi.org/10.1182/blood.V126.23.3995.3995

Published: 2015

Journal Articles

Postranslationally Modified Proteins in the Central Nervous System (CNS) Are the Dominant Antigenic Target/Stimulus of the B-Cell Receptor (BCR) in Primary CNS Lymphomas (PCNSL) Providing Strong Evidence for the Role of Chronic Autoantigenic Stimulation As an Early Step in the Pathogenesis of Aggressive B-Cell Lymphomas

Lorenz Thurner, MD, Maria Kemele, Natalie Fadle, Evi Regitz, Patrick Roth, MD, Michael Weller, Prof., Monika Szczepanowski, Wolfram Klapper, Camelia-Maria Monoranu, MD, Andreas Rosenwald, MD, Rolf Buslei, MD, Rainer Maria Bohle, MD, Yoo-Jin Kim, MD, Klaus-Dieter Preuss, PhD, Michael Pfreundschuh

Blood (2014) 124 (21): 142.

https://doi.org/10.1182/blood.V124.21.142.142

Published: 2014

NARROW

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

B-Cell Receptor Antigens As the Targeting Moiety for Bispecific Constructs - a Novel Treatment Approach for B-Cell Lymphomas

CD3/Bars: A Novel Bispecific Format for the Treatment of B-Cell Lymphomas

LRPAP1 Is a Frequent B-Cell Receptor Antigen in Mantle Cell Lymphoma (MCL)

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only